Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome: A Randomized Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS)

Trial Profile

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome: A Randomized Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Eptifibatide (Primary)
  • Indications Acute coronary syndromes; Myocardial ischaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms EARLY-ACS
  • Sponsors Merck & Co
  • Most Recent Events

    • 09 Nov 2012 Planned number of patients changed from 9500 to 10500 as reported by European Clinical Trials Database record.
    • 30 Mar 2009 Results presented at the American College of Cardiology meeting and reported in the New England Journal of Medicine, as reported by Schering-Plough.
    • 30 Mar 2009 Results were published in the New England Journal of Medicine and presented as a late-breaking clinical trial during the American College of Cardiology's 58th annual scientific session.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top